Verily has enlisted Amy Abernethy, the FDA’s former principal deputy commissioner and acting chief information officer, as its next president of clinical research.

Abernethy, who left the FDA in April, is recognized for spearheading changes in the way the agency uses data by accelerating adoption of cloud-based data interoperability and progressing the FDA’s work in the areas of real-world evidence and personalized medicine.

At Verily, which is owned by Google parent company Alphabet, Abernethy will join Robert Califf, the former FDA commissioner from 2016-2017, who is now serving as the biotech’s head of clinical policy and strategy.

“There is no one better positioned to catapult Verily’s clinical research business into its next important phase than Amy, with her understanding of clinical practice, research, data science and the evolving regulatory environment,” said Andy Conrad, Verily’s CEO and founder.

Abernethy was with the FDA for two years before her departure. Prior to that, she worked in the private sector, including with CareDx, Roche’s Flatiron Health and Athena Health.